VOGELXO Drug Patent Profile
✉ Email this page to a colleague
When do Vogelxo patents expire, and when can generic versions of Vogelxo launch?
Vogelxo is a drug marketed by Upsher Smith Labs and is included in one NDA. There are three patents protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in VOGELXO is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vogelxo
A generic version of VOGELXO was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VOGELXO?
- What are the global sales for VOGELXO?
- What is Average Wholesale Price for VOGELXO?
Summary for VOGELXO
| International Patents: | 7 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 1 |
| Patent Applications: | 5,003 |
| Drug Prices: | Drug price information for VOGELXO |
| What excipients (inactive ingredients) are in VOGELXO? | VOGELXO excipients list |
| DailyMed Link: | VOGELXO at DailyMed |
Recent Clinical Trials for VOGELXO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Upsher-Smith Laboratories | Phase 4 |
Pharmacology for VOGELXO
| Drug Class | Androgen |
| Mechanism of Action | Androgen Receptor Agonists |
US Patents and Regulatory Information for VOGELXO
VOGELXO is protected by three US patents.
Patents protecting VOGELXO
Testosterone gel compositions and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
Testosterone gel compositions and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
Testosterone gel compositions and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | VOGELXO | testosterone | GEL, METERED;TRANSDERMAL | 204399-003 | Jun 4, 2014 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Upsher Smith Labs | VOGELXO | testosterone | GEL;TRANSDERMAL | 204399-002 | Jun 4, 2014 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Upsher Smith Labs | VOGELXO | testosterone | GEL, METERED;TRANSDERMAL | 204399-003 | Jun 4, 2014 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Upsher Smith Labs | VOGELXO | testosterone | GEL, METERED;TRANSDERMAL | 204399-003 | Jun 4, 2014 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VOGELXO
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott UK Ltd. | Intrinsa | testosterone | EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
| Warner Chilcott Deutschland GmbH | Livensa | testosterone | EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VOGELXO
See the table below for patents covering VOGELXO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | 201711535 | Print circuit board and method for manufacturing same | ⤷ Sign Up |
| European Patent Office | 3079703 | TESTOSTERONE GEL COMPOSITIONS AND RELATED METHODS | ⤷ Sign Up |
| European Patent Office | 3079703 | ⤷ Sign Up | |
| China | 106376169 | 电路板及其制作方法 (Circuit board and manufacturing method thereof) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
